King MC, Levy-Lahad E, Lahad A (2014) Population-based screening for BRCA1 and BRCA2: 2014 Lasker award. JAMA 312(11):1091–1092

Article  CAS  PubMed  Google Scholar 

Claus EB et al (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77(11):2318–2324

Article  CAS  PubMed  Google Scholar 

Garber JE, Offit K (2005) Hereditary cancer predisposition syndromes. J Clin Oncol 23(2):276–292

Article  PubMed  Google Scholar 

Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416

Article  CAS  PubMed  Google Scholar 

Rebbeck TR et al (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87

Article  CAS  PubMed  PubMed Central  Google Scholar 

Domchek SM et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229

Article  CAS  PubMed  Google Scholar 

Domchek SM et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maxwell KN et al (2016) Population frequency of germline BRCA1/2 mutations. J Clin Oncol 34(34):4183–4185

Article  PubMed  Google Scholar 

Thompson ER et al (2016) Panel testing for Familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol 34(13):1455–1459

Article  CAS  PubMed  Google Scholar 

Antoniou AC et al (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580–1590

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans DG et al (2017) Pathology update to the Manchester scoring system based on testing in over 4000 families. J Med Genet 54(10):674–681

Article  CAS  PubMed  Google Scholar 

National Institute for Health and Care Excellence (NICE). 4/24/2024]; Available from: https://www.nice.org.uk/

Ebrahimi E et al (2019) The NCCN criterion young age at onset alone is not an indicator of hereditary breast cancer in Iranian population. Cancer Prev Res (Phila) 12(11):763–770

Article  PubMed  Google Scholar 

NCCN Guidelines Available from: https://www.nccn.org/guidelines/category_2

Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405–424

Article  PubMed  PubMed Central  Google Scholar 

Tutt ANJ et al (2021) Adjuvant Olaparib for patients with BRCA1- or BRCA2-Mutated breast cancer. N Engl J Med 384(25):2394–2405

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akbari ME et al (2023) Ten-Year survival of breast cancer in Iran: A National study (Retrospective cohort study). Breast Care (Basel) 18(1):12–21

Article  PubMed  Google Scholar 

Guzmán-Arocho YD et al (2022) Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer 126(2):302–309

Article  PubMed  Google Scholar 

Copson ER et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169–180

Article  CAS  PubMed  PubMed Central  Google Scholar 

John EM et al (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US Racial/ethnic groups. JAMA 298(24):2869–2876

Article  CAS  PubMed  Google Scholar 

Hall MJ et al (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115(10):2222–2233

Article  CAS  PubMed  Google Scholar 

Mavaddat N et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21(1):134–147

Article  CAS  PubMed  Google Scholar 

Farra C et al (2019) BRCA mutation screening and patterns among high-risk Lebanese subjects. Hered Cancer Clin Pract 17:4

Article  PubMed  PubMed Central  Google Scholar 

van Wyk C et al (2024) The Manchester scoring system for predicting BRCA1/2 mutations underperforms in Arabic Omani breast cancer patients. J Genet Couns

Rebbeck TR et al (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39(5):593–620

Article  CAS  PubMed  Google Scholar 

Bhaskaran SP et al (2019) Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. Int J Cancer 145(4):962–973

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friebel TM et al (2019) BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat 40(10):1781–1796

Article  PubMed  Google Scholar 

Kurian AW et al (2019) Genetic testing and results in a Population-Based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol 37(15):1305–1315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lou DI et al (2014) Rapid evolution of BRCA1 and BRCA2 in humans and other primates. BMC Evol Biol 14:155

Article  PubMed  PubMed Central  Google Scholar